story_08e2a971-6083-5132-9081-db15d639c185New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Verified signal
Johnson & Johnson: 1 verified canonical event across 1 event type, supported by 1 independent source domain.
Why it matters
Verified with 1 independent source domain, 7 evidence object(s), 4 grounded fact(s), and confidence 0.80.
Evidence graph
evt_81d7eb61-5afb-5af9-a6ee-f0d1b9880db2evd_2e28f506-4e40-55a0-bab9-2bfd83423db5, evd_6d5875f0-a119-58c8-a135-5ed6b99eedbd, evd_8f041091-4876-5456-9906-15de65d2994e, evd_b24182a2-815e-5503-bbf2-e9ade231dc60, evd_c0b165ff-f3e9-5910-b373-6c0c2f2adfef, evd_ec9babc1-f0a9-52c4-9d6f-014553576f04, evd_fefffb30-d08e-5e56-a562-4707bc94da1bfact_215d0c20-1ec9-5b35-a53c-32d2711dcd7d, fact_6a289db6-64de-5916-9141-9a47a7d76413, fact_7a849c8f-3ab2-58d1-bad6-6d2401a72569, fact_afef352a-c0a9-5353-99b4-f61d21581347rel_51ace27e-6045-5bbf-a5cd-f250507f21ee, rel_c96d6a34-8b9a-5ce6-ab73-a1a38f8954a2